专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

US20120070875A1 Amino Acid Sequences which Enhance Peptide Conjugate Solubility 有权
标题翻译：增强肽结合物溶解度的氨基酸序列
公开(公告)号：US20120070875A1
公开(公告)日：2012-03-22
申请号：US13322914
申请日：2010-05-27
申请人： Richard H. Weisbart
发明人： Richard H. Weisbart
IPC分类号： C12N9/96 , C07K14/00 , C07K16/00 , C07K7/06 , C07K5/10 , C07K9/00 , C07K7/08
CPC分类号： A61K47/48538 , A61K47/48415 , A61K47/6811 , A61K47/6843 , C07K16/44 , C07K2317/77 , C07K2319/02 , C07K2319/036 , C07K2319/21 , C07K2319/41 , C12N15/625
摘要： The present invention provides peptide conjugates having improved solubility as well as increased secretion during cell based production, as well as methods of utilizing such peptides. The peptide conjugates include a short peptide domain defined by the amino acid sequence AGIH (SEQ ID NO: 8) and may include a biologically active molecule useful in intracellular and intranuclear transport of the biologically active molecule to treat various disorders and diseases.
摘要翻译：本发明提供具有改善的溶解性以及在基于细胞的生产期间增加的分泌以及利用这些肽的方法的肽缀合物。肽缀合物包括由氨基酸序列AGIH（SEQ ID NO：8）定义的短肽结构域，并且可以包括可用于生物活性分子的细胞内和核内运输以治疗各种疾病和疾病的生物活性分子。

12. 发明申请

US20080292618A1 INTRANUCLEAR PROTEIN TRANSDUCTION THROUGH A NUCLEOSIDE SALVAGE PATHWAY 有权
标题翻译：通过核糖体途径途径进行内分泌蛋白转运
公开(公告)号：US20080292618A1
公开(公告)日：2008-11-27
申请号：US12126810
申请日：2008-05-23
申请人： Richard H. Weisbart
发明人： Richard H. Weisbart
IPC分类号： A61K39/395 , A61K31/70 , A61K38/00 , A61K38/43 , C12Q1/02 , A61P19/00 , A61P31/00 , A61P37/00
CPC分类号： A61K47/48538 , A61K31/713 , A61K38/00 , A61K47/6843 , C07K16/44 , C07K2317/622 , C07K2317/77 , C07K2317/82 , C12N15/113 , C12N2310/14 , C12N2310/3513 , C12N2320/30 , G01N33/5035
摘要： Provided herein are conjugate molecules containing a substrate for a nucleoside transport pathway linked to an active agent, wherein the conjugate can be transported into a cell or into the nucleus of a cell via a cellular nucleoside transport pathway. Further provided are methods of delivering a conjugate molecule to a target cell expressing a nucleoside transport pathway, wherein the conjugate contains a substrate for the nucleoside transport pathway linked to an active agent. Also provided are methods for screening for conjugates that are transported by nucleoside transport pathways. Further provided are methods of treating a patient having a disease or disorder affecting tissues expressing nucleoside transport pathways, in which a conjugate containing an agent effective in treating the disorder is administered to the patient. Also provided are methods of treating a patient having an autoimmune disorder involving administering to the patient a compound that inhibits a nucleoside transport pathway.
摘要翻译：本文提供了含有与活性剂连接的核苷转运途径的底物的缀合物分子，其中可通过细胞核转运途径将缀合物转运至细胞或细胞核中。还提供了将共轭分子递送到表达核苷转运途径的靶细胞的方法，其中所述缀合物含有与活性剂连接的核苷转运途径的底物。还提供了筛选通过核苷转运途径转运的缀合物的方法。还提供了治疗患有影响表达核苷转运途径的组织的疾病或病症的患者的方法，其中将含有有效治疗病症的药物的缀合物施用于患者。还提供了治疗患有自身免疫疾病的患者的方法，其涉及向患者施用抑制核苷转运途径的化合物。

13. 发明授权

US09155801B2 Amino acid sequences which enhance peptide conjugate solubility 有权
标题翻译：提高肽缀合物溶解度的氨基酸序列
公开(公告)号：US09155801B2
公开(公告)日：2015-10-13
申请号：US13322914
申请日：2010-05-27
申请人： Richard H. Weisbart
发明人： Richard H. Weisbart
IPC分类号： A61K47/48 , C07K16/44 , C12N15/62
CPC分类号： A61K47/48538 , A61K47/48415 , A61K47/6811 , A61K47/6843 , C07K16/44 , C07K2317/77 , C07K2319/02 , C07K2319/036 , C07K2319/21 , C07K2319/41 , C12N15/625
摘要： The present invention provides peptide conjugates having improved solubility as well as increased secretion during cell based production, as well as methods of utilizing such peptides. The peptide conjugates include a short peptide domain defined by the amino acid sequence AGIH (SEQ ID NO: 8) and may include a biologically active molecule useful in intracellular and intranuclear transport of the biologically active molecule to treat various disorders and diseases.
摘要翻译：本发明提供具有改善的溶解性以及在基于细胞的生产期间增加的分泌以及利用这些肽的方法的肽缀合物。肽缀合物包括由氨基酸序列AGIH（SEQ ID NO：8）定义的短肽结构域，并且可以包括可用于生物活性分子的细胞内和核内运输以治疗各种疾病和疾病的生物活性分子。

14. 发明授权

US09133460B2 Methods for determining and inhibiting rheumatoid arthritis associated with the BRAF oncogene in a subject 有权
标题翻译：用于测定和抑制受试者中与BRAF致癌基因相关的类风湿性关节炎的方法
公开(公告)号：US09133460B2
公开(公告)日：2015-09-15
申请号：US14218577
申请日：2014-03-18
申请人： Richard H. Weisbart
发明人： Richard H. Weisbart
IPC分类号： C12N15/11 , C12Q1/25 , C12N15/113 , G01N33/564 , C12Q1/68 , A61K31/166 , A61K31/4155 , A61K31/4184 , A61K31/426 , A61K31/451 , A61K31/501 , C12Q1/48
CPC分类号： C12N15/1135 , A61K31/166 , A61K31/4155 , A61K31/4184 , A61K31/426 , A61K31/451 , A61K31/501 , C12Q1/485 , C12Q1/6883 , C12Q2600/156 , C12Q2600/158 , G01N33/564 , G01N2333/82 , G01N2800/102
摘要： The invention provides methods for determining whether a subject is suffering from a rheumatoid arthritis associated with the BRAF oncogene comprising contacting isolated fibroblasts from the subject with a molecule or pool of molecules directed to the BRAF oncogene; and culturing the sample in the presence of the agent and determining whether BRAF oncogene expression by the cell is decreased and/or whether cells in the sample return to a less transformed phenotype, exhibit decreased cell proliferation and/or exhibit increased contact inhibition, any of which is indicative that the subject is suffering from a rheumatoid arthritis associated with the BRAF oncogene.
摘要翻译：本发明提供了用于确定受试者是否患有与BRAF致癌基因相关的类风湿性关节炎的方法，其包括将来自受试者的分离的成纤维细胞与分子或指向BRAF癌基因的分子池接触; 并且在试剂存在下培养样品并确定细胞中BRAF癌基因表达是否降低和/或样品中的细胞是否返回到较少转化的表型，显示降低的细胞增殖和/或显示增加的接触抑制，任何这表明该受试者患有与BRAF癌基因相关的类风湿性关节炎。

15. 发明授权

US4812397A MAB-anti-DNA related to nephritis 失效
标题翻译：与肾炎相关的MAB-抗DNA
公开(公告)号：US4812397A
公开(公告)日：1989-03-14
申请号：US12830
申请日：1987-02-10
申请人： Richard H. Weisbart
发明人： Richard H. Weisbart
IPC分类号： G01N33/564 , G01N33/68 , G01N33/00 , G01N33/53
CPC分类号： G01N33/686 , G01N33/564 , Y10S436/811
摘要： Novel compositions and methods are provided for detecting lupus nephritis in patients suffering from SLE. Competitive or non-competitive assays may be employed, where monoconal antibodies may be used to compete with antiserum for a nucleic acid ligand or may be used for the detection of antiidiotype antibodies as diagnostic of the presence or absence of lupus nephritis.
摘要翻译：提供新的组合物和方法用于在患有SLE的患者中检测狼疮性肾炎。可以使用竞争性或非竞争性测定法，其中可以使用单核抗体与抗血清竞争核酸配体，或者可以用于检测抗体型抗体，作为有无狼疮性肾炎的诊断。

16. 发明授权

US08680066B2 Methods for determining and inhibiting rheumatoid arthritis associated with the BRAF oncogene in a subject 有权
标题翻译：用于测定和抑制受试者中与BRAF致癌基因相关的类风湿性关节炎的方法
公开(公告)号：US08680066B2
公开(公告)日：2014-03-25
申请号：US13440942
申请日：2012-04-05
申请人： Richard H. Weisbart
发明人： Richard H. Weisbart
IPC分类号： C12N15/11 , C12Q1/68
CPC分类号： C12N15/1135 , A61K31/166 , A61K31/4155 , A61K31/4184 , A61K31/426 , A61K31/451 , A61K31/501 , C12Q1/485 , C12Q1/6883 , C12Q2600/156 , C12Q2600/158 , G01N33/564 , G01N2333/82 , G01N2800/102
摘要： The invention provides methods for determining whether a subject is suffering from a rheumatoid arthritis associated with the BRAF oncogene comprising contacting isolated fibroblasts from the subject with a molecule or pool of molecules directed to the BRAF oncogene; and culturing the sample in the presence of the agent and determining whether BRAF oncogene expression by the cell is decreased and/or whether cells in the sample return to a less transformed phenotype, exhibit decreased cell proliferation and/or exhibit increased contact inhibition, any of which is indicative that the subject is suffering from a rheumatoid arthritis associated with the BRAF oncogene.
摘要翻译：本发明提供了用于确定受试者是否患有与BRAF致癌基因相关的类风湿性关节炎的方法，其包括将来自受试者的分离的成纤维细胞与分子或指向BRAF癌基因的分子池接触; 并且在试剂存在下培养样品并确定细胞中BRAF癌基因表达是否降低和/或样品中的细胞是否返回到较少转化的表型，显示降低的细胞增殖和/或显示增加的接触抑制，任何这表明该受试者患有与BRAF癌基因相关的类风湿性关节炎。

17. 发明申请

US20120258461A1 METHODS FOR DETERMINING AND INHIBITING RHEUMATOID ARTHRITIS ASSOCIATED WITH THE BRAF ONCOGENE IN A SUBJECT 有权
标题翻译：用于确定和抑制与受影响的BRAF ONCOGENE相关的流感嗜血杆菌的方法
公开(公告)号：US20120258461A1
公开(公告)日：2012-10-11
申请号：US13440942
申请日：2012-04-05
申请人： Richard H. Weisbart
发明人： Richard H. Weisbart
IPC分类号： C12Q1/68 , C12N5/071
CPC分类号： C12N15/1135 , A61K31/166 , A61K31/4155 , A61K31/4184 , A61K31/426 , A61K31/451 , A61K31/501 , C12Q1/485 , C12Q1/6883 , C12Q2600/156 , C12Q2600/158 , G01N33/564 , G01N2333/82 , G01N2800/102
摘要： The invention provides methods for determining whether a subject is suffering from a rheumatoid arthritis associated with the BRAF oncogene comprising contacting isolated fibroblasts from the subject with a molecule or pool of molecules directed to the BRAF oncogene; and culturing the sample in the presence of the agent and determining whether BRAF oncogene expression by the cell is decreased and/or whether cells in the sample return to a less transformed phenotype, exhibit decreased cell proliferation and/or exhibit increased contact inhibition, any of which is indicative that the subject is suffering from a rheumatoid arthritis associated with the BRAF oncogene.
摘要翻译：本发明提供了用于确定受试者是否患有与BRAF致癌基因相关的类风湿性关节炎的方法，其包括将来自受试者的分离的成纤维细胞与分子或指向BRAF癌基因的分子池接触; 并且在试剂存在下培养样品并确定细胞中BRAF癌基因表达是否降低和/或样品中的细胞是否返回到较少转化的表型，显示降低的细胞增殖和/或显示增加的接触抑制，任何这表明该受试者患有与BRAF癌基因相关的类风湿性关节炎。

18. 发明申请

US20100143358A1 Use of Antibody Conjugates 审中-公开
标题翻译：抗体缀合物的使用
公开(公告)号：US20100143358A1
公开(公告)日：2010-06-10
申请号：US12523438
申请日：2008-01-22
申请人： Richard H. Weisbart
发明人： Richard H. Weisbart
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： C07K16/44 , A61K38/1758 , A61K47/6851 , C07K2317/14 , C07K2317/622 , C07K2317/73 , C07K2317/77 , C07K2317/92 , C07K2319/01 , C07K2319/30
摘要： Provided herein are methods for inducing growth arrest or apoptosis in cancer cells in a subject. Further provided are methods of inhibiting or treating metastasis of a cancer cell in a subject. The methods involve administering to the subject an antibody conjugate containing an antibody, variant thereof, or functional fragment thereof having binding specificity of the antibody as produced by the hybridoma having ATCC accession number PTA 2439 and a biologically active molecule. The antibody (e.g., mAb 3E10) variant or functional fragment thereof provides for the in vivo transduction of the conjugate to the nucleus of mammalian cells, where the conjugated biologically active molecule may exert its effect. In particular embodiments, the antibody conjugate comprises a single chain Fv fragment of an antibody having the binding specificity of mAb 3E10 produced by ATCC PTA 2439, conjugated to p53.
摘要翻译：本文提供了用于诱导受试者的癌细胞中生长停滞或细胞凋亡的方法。还提供了抑制或治疗受试者中癌细胞转移的方法。所述方法包括向受试者施用含有抗体的抗体缀合物，其具有由具有ATCC登录号PTA 2439和生物活性分子的杂交瘤产生的具有抗体结合特异性的抗体，其变体或其功能片段。抗体（例如，mAb 3E10）变体或其功能片段提供缀合物向哺乳动物细胞核的体内转导，其中缀合的生物活性分子可发挥其作用。在具体实施方案中，抗体缀合物包含具有与p53缀合的ATCC PTA 2439产生的mAb 3E10的结合特异性的抗体的单链Fv片段。

19. 发明授权

US08956825B2 Intranuclear protein transduction through a nucleoside salvage pathway 有权
标题翻译：通过核苷补救途径的核内蛋白转导
公开(公告)号：US08956825B2
公开(公告)日：2015-02-17
申请号：US12126810
申请日：2008-05-23
申请人： Richard H. Weisbart
发明人： Richard H. Weisbart
IPC分类号： G01N33/53 , G01N33/58 , G01N33/577 , C07K16/44 , C07K16/46 , A61K47/48 , G01N33/50 , A61K38/00
CPC分类号： A61K47/48538 , A61K31/713 , A61K38/00 , A61K47/6843 , C07K16/44 , C07K2317/622 , C07K2317/77 , C07K2317/82 , C12N15/113 , C12N2310/14 , C12N2310/3513 , C12N2320/30 , G01N33/5035
摘要： Provided herein are conjugate molecules containing a substrate for a nucleoside transport pathway linked to an active agent, wherein the conjugate can be transported into a cell or into the nucleus of a cell via a cellular nucleoside transport pathway. Further provided are methods of delivering a conjugate molecule to a target cell expressing a nucleoside transport pathway, wherein the conjugate contains a substrate for the nucleoside transport pathway linked to an active agent. Also provided are methods for screening for conjugates that are transported by nucleoside transport pathways. Further provided are methods of treating a patient having a disease or disorder affecting tissues expressing nucleoside transport pathways, in which a conjugate containing an agent effective in treating the disorder is administered to the patient. Also provided are methods of treating a patient having an autoimmune disorder involving administering to the patient a compound that inhibits a nucleoside transport pathway.
摘要翻译：本文提供了含有与活性剂连接的核苷转运途径的底物的缀合物分子，其中可通过细胞核转运途径将缀合物转运至细胞或细胞核中。还提供了将共轭分子递送到表达核苷转运途径的靶细胞的方法，其中所述缀合物含有与活性剂连接的核苷转运途径的底物。还提供了筛选通过核苷转运途径转运的缀合物的方法。还提供了治疗患有影响表达核苷转运途径的组织的疾病或病症的患者的方法，其中将含有有效治疗病症的药物的缀合物施用于患者。还提供了治疗患有自身免疫疾病的患者的方法，其涉及向患者施用抑制核苷转运途径的化合物。

20. 发明授权

US06200565B1 Oral administration of immunoglobulins for treating autoimmune hearing loss 有权
标题翻译：口服免疫球蛋白治疗自身免疫性听力损失
公开(公告)号：US06200565B1
公开(公告)日：2001-03-13
申请号：US09306772
申请日：1999-05-07
申请人： Richard H. Weisbart
发明人： Richard H. Weisbart
IPC分类号： A61K39395
CPC分类号： C07K16/00 , A61K2039/505 , C07K2317/21
摘要： The present invention is directed to methods of treating autoimmune sensorineural hearing loss in a patient by orally administering a human immunoglobulin preparation to the patient.
摘要翻译：本发明涉及通过向患者口服施用人免疫球蛋白制剂来治疗患者的自身免疫性感觉神经性听力损失的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式